SM
IMDZ

Sabby Management’s Immune Design Corp. IMDZ Stock Holding History

Sabby Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,000
Closed -$244K – 429
2015
Q3 		$244K Buy
+20,000
New +$375K 0.01% 342

Other funds holding IMDZ

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's IMDZ Position: Q4 2015 in Review

Sabby Management sold out of Immune Design Corp. (IMDZ) in Q4 2015, closing a stake of 20,000 shares — an estimated $244K sold.

Sabby Management first reported a position in IMDZ in Q3 2015 and held it in 1 quarter. The position peaked at $244K in Q3 2015. 67 funds tracked by Wall St. Rank hold IMDZ as of Q4 2015.

  • Sabby Management reported no remaining Immune Design Corp. position as of Q4 2015 after selling out during the quarter.
  • Sabby Management sold 20,000 Immune Design Corp. shares in Q4 2015, an estimated $244K.
  • Sabby Management first reported a position in Immune Design Corp. in Q3 2015 and held it in 1 quarter.
  • Sabby Management's Immune Design Corp. position peaked at $244K in Q3 2015.
  • 67 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.